.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Teva
Moodys
McKesson
Healthtrust
Covington
Boehringer Ingelheim
Chubb
Daiichi Sankyo

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,208,141

« Back to Dashboard

Which drugs does patent 7,208,141 protect, and when does it expire?


Patent 7,208,141 protects CAYSTON and is included in one NDA.

This patent has thirty-nine patent family members in eighteen countries.

Summary for Patent: 7,208,141

Title:Inhalable aztreonam aerosol for treatment and prevention of pulmonary bacterial infections
Abstract:A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam, or a pharmaceutically acceptable salt thereof, delivered as an aerosol or dry powder formulation.
Inventor(s): Montgomery; Alan Bruce (Seattle, WA)
Assignee: Corus Pharma, Inc. (Seattle, WA)
Application Number:10/654,815
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Gilead
CAYSTON
aztreonam
FOR SOLUTION;INHALATION050814-001Feb 22, 2010RXYesYes► Subscribe► SubscribeY IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,208,141

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,660,249 Inhalable dry powder aztreonam for treatment and prevention of pulmonary bacterial infections► Subscribe
7,427,633Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections► Subscribe
8,399,496Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections► Subscribe
9,533,000Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections► Subscribe
9,345,663Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections► Subscribe
8,841,286Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections► Subscribe
7,214,364Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections► Subscribe
7,138,419Process for manufacturing bulk solutions and a lyophilized pure .alpha.-aztreonam lysinate► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,208,141

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia1641436► Subscribe
Portugal1641436► Subscribe
Portugal2301524► Subscribe
Portugal1353647► Subscribe
Norway20101377► Subscribe
Norway2011001► Subscribe
Norway329643► Subscribe
Norway20032946► Subscribe
Luxembourg91851► Subscribe
Japan2007527398► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
QuintilesIMS
Fuji
Baxter
Boehringer Ingelheim
Julphar
Cipla
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot